Weaver Capital Management LLC Buys 5,560 Shares of Edwards Lifesciences Co. (NYSE:EW)

Weaver Capital Management LLC raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 108.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 10,688 shares of the medical research company’s stock after purchasing an additional 5,560 shares during the period. Weaver Capital Management LLC’s holdings in Edwards Lifesciences were worth $791,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of EW. Algert Global LLC grew its holdings in Edwards Lifesciences by 38.4% during the second quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock valued at $426,000 after purchasing an additional 1,280 shares during the period. Czech National Bank grew its holdings in Edwards Lifesciences by 6.9% during the third quarter. Czech National Bank now owns 122,715 shares of the medical research company’s stock valued at $8,098,000 after purchasing an additional 7,883 shares during the period. GAMMA Investing LLC lifted its position in shares of Edwards Lifesciences by 21.6% in the third quarter. GAMMA Investing LLC now owns 4,105 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 730 shares in the last quarter. Alpha Financial Partners LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at about $693,000. Finally, Diversified Trust Co lifted its position in shares of Edwards Lifesciences by 2.4% in the third quarter. Diversified Trust Co now owns 26,649 shares of the medical research company’s stock valued at $1,759,000 after acquiring an additional 620 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,000 shares of company stock valued at $547,430. 1.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. Morgan Stanley restated an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Citigroup boosted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, The Goldman Sachs Group boosted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Trading Down 0.1 %

EW opened at $71.33 on Wednesday. The stock has a market cap of $42.07 billion, a price-to-earnings ratio of 10.29, a P/E/G ratio of 3.72 and a beta of 1.11. The stock’s 50 day moving average price is $72.49 and its 200-day moving average price is $69.63. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.